Aratana Therapeutics, Inc. (NASDAQ:PETX) has earned an average rating of “Hold” from the eight analysts that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $9.00.

PETX has been the topic of a number of research analyst reports. HC Wainwright initiated coverage on shares of Aratana Therapeutics in a research report on Friday, November 17th. They set a “buy” rating and a $10.00 price target on the stock. Jefferies Group set a $9.00 price target on shares of Aratana Therapeutics and gave the company a “buy” rating in a research report on Thursday, November 16th. Zacks Investment Research raised shares of Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 price target on the stock in a research report on Thursday, November 9th. Lake Street Capital cut their price target on shares of Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 25th. Finally, ValuEngine cut shares of Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.

In other news, major shareholder Healthcare Master Fun Broadfin sold 890,516 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $5.70, for a total transaction of $5,075,941.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Peter Steven St sold 50,000 shares of the stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $6.24, for a total transaction of $312,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 1,127,032 shares of company stock worth $6,622,391 in the last three months. Insiders own 5.20% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in PETX. Janus Henderson Group PLC bought a new position in shares of Aratana Therapeutics during the 2nd quarter worth about $12,948,000. Broadfin Capital LLC raised its holdings in shares of Aratana Therapeutics by 40.3% in the 2nd quarter. Broadfin Capital LLC now owns 5,184,942 shares of the biopharmaceutical company’s stock worth $37,487,000 after acquiring an additional 1,489,500 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Aratana Therapeutics by 11.2% in the 2nd quarter. Franklin Resources Inc. now owns 6,011,309 shares of the biopharmaceutical company’s stock worth $43,462,000 after acquiring an additional 604,518 shares during the last quarter. AWM Investment Company Inc. raised its holdings in shares of Aratana Therapeutics by 49.4% in the 2nd quarter. AWM Investment Company Inc. now owns 1,587,620 shares of the biopharmaceutical company’s stock worth $11,478,000 after acquiring an additional 525,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Aratana Therapeutics by 197.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 380,895 shares of the biopharmaceutical company’s stock worth $2,754,000 after acquiring an additional 252,655 shares during the last quarter. 73.95% of the stock is currently owned by institutional investors.

Shares of Aratana Therapeutics (NASDAQ PETX) traded up $0.16 on Monday, reaching $5.59. 299,100 shares of the company’s stock were exchanged, compared to its average volume of 415,869. The company has a current ratio of 3.42, a quick ratio of 3.08 and a debt-to-equity ratio of 0.26. Aratana Therapeutics has a twelve month low of $4.97 and a twelve month high of $8.63.

Aratana Therapeutics (NASDAQ:PETX) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.03. The business had revenue of $6.16 million for the quarter, compared to analysts’ expectations of $6.47 million. Aratana Therapeutics had a negative net margin of 358.55% and a negative return on equity of 48.79%. The business’s quarterly revenue was up 1440.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.38) earnings per share. sell-side analysts predict that Aratana Therapeutics will post -1.03 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/11/aratana-therapeutics-inc-petx-receives-average-recommendation-of-hold-from-brokerages.html.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Analyst Recommendations for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.